Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).

Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95. doi: 10.1164/rccm.201202-0314OC. Epub 2012 May 3.

2.

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.

PMID:
20007927
3.

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J.

Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7.

PMID:
21474646
4.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

PMID:
24476390
5.

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*.

Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Erratum in: Ann Intern Med. 2014 May 6;160(9):658.

PMID:
23648946
6.

The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy.

Parra D, Beckey NP, Stevens GR.

Pharmacotherapy. 2007 May;27(5):675-83.

PMID:
17461702
7.

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G.

N Engl J Med. 2014 May 29;370(22):2093-101. doi: 10.1056/NEJMoa1401739. Epub 2014 May 18.

8.

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?

Kubo H, Yanai M, Azuma A.

Am J Respir Crit Care Med. 2013 May 1;187(9):1029-30. doi: 10.1164/rccm.201210-1782LE. No abstract available.

PMID:
23634865
9.

Reply: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?

Noth I, Olman M; IPFnet.

Am J Respir Crit Care Med. 2013 May 1;187(9):1030. doi: 10.1164/rccm.201211-2060LE. No abstract available.

PMID:
23634866
10.

Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation.

Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS.

Pharmacotherapy. 2000 Oct;20(10):1159-66.

PMID:
11034038
11.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

12.

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators.

N Engl J Med. 2003 Apr 10;348(15):1425-34. Epub 2003 Feb 24.

13.

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.

Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan.

Respir Res. 2011 Jul 15;12:93. doi: 10.1186/1465-9921-12-93.

14.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
15.

[Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].

Couturaud F, Pernod G, Pison C, Mismetti P, Sanchez O, Meyer G, Parent F, Girard P, Simonneau G, Drouet L, Gueret P, Jego P, Delaval P, Duhamel E, Gruel Y, Delahousse B, Regina S, Pottier P, Connaud J, Lecomte F, Provost K, Vilmans N, Gosset X, Bura-Rivière A, Meach G, Lacut K, Bosson JL, Guillot K, Mottier D, Leroyer C.

Rev Mal Respir. 2008 Sep;25(7):885-93. French.

PMID:
18946418
16.

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators.

Am Heart J. 2010 Mar;159(3):331-9. doi: 10.1016/j.ahj.2009.07.035. Erratum in: Am Heart J. 2010 Jun;159(6):1162.

PMID:
20211292
17.

Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA; Warfarin-Associated Research Projects and Other Endeavors Consortium.

Pharmacotherapy. 2008 Aug;28(8):960-7. doi: 10.1592/phco.28.8.960.

PMID:
18657012
18.

Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study.

Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio AM.

Arch Intern Med. 2010 Apr 12;170(7):609-16. doi: 10.1001/archinternmed.2010.49.

PMID:
20386004
19.

The efficacy of 3-mg warfarin initiating dose in adult Thai patients, who required long-term anticoagulant therapy.

Suwanawiboon B, Kongtim P, Chinthammitr Y, Ruchutrakool T, Wanachiwanawin W.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S225-31.

PMID:
21721451
20.

The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.

Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S.

J Card Fail. 2004 Apr;10(2):101-12.

PMID:
15101020
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk